Older patients with asthma are at increased risk for treatment failure, particularly those patients being treated with inhaled steroids, says a new study.
"Asthma morbidity and mortality are known to be increased in middle-aged and older patients, and gender may also affect the incidence and course of the disease, but the impact of age and gender on asthma treatment response is not well understood.
"In our study of 1,200 patients with mild-to-moderate asthma, the risk of treatment failure was increased in patients aged 30 and above, and these failure rates increased proportionally with increasing age above age 30 across our study cohort," said study author Michael Wechsler, professor of medicine at the National Jewish Health in Denver, US.
"We also found that the rate of treatment failure did not significantly differ between males and females," Wechsler said.
The findings were published online in the American Journal of Respiratory and Critical Care Medicine.
The researchers used Asthma Clinical Research Network data on patients participating in 10 trials from 1993 to 2003.
Treatment failures were observed in 17.3 percent of patients 30 years old and above, compared with 10.3 percent of those under age 30.
Lower lung function measurements and longer duration of asthma were associated with a higher risk of treatment failure.
When stratified by specific treatment, failures increased consistently for every year above age 30 among those patients using inhaled corticosteroids.
Patients aged 30 and older who were treated with inhaled corticosteroids, either alone or in combination, had more than twice the risk of experiencing a treatment failure compared with patients younger than 30.
Males and females had similar asthma control measures and treatment failure rates.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
